200 related articles for article (PubMed ID: 35061161)
1. Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling.
Tanveer A; Hussain K; Tasneem H; Arif I; Rashid M; Abbas N; Shamim R; Shah PA; Bukhari NI
J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):311-323. PubMed ID: 35061161
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes.
Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Choi CI
Arch Pharm Res; 2023 Dec; 46(11-12):939-953. PubMed ID: 38064121
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes.
Whang SS; Cho CK; Jung EH; Kang P; Park HJ; Lee YJ; Choi CI; Bae JW; Kim HS; Jang CG; Lee SY
Arch Pharm Res; 2022 Aug; 45(8):584-595. PubMed ID: 36028591
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.
Cho CK; Park HJ; Kang P; Moon S; Lee YJ; Bae JW; Jang CG; Lee SY
Arch Pharm Res; 2021 Dec; 44(12):1076-1090. PubMed ID: 34807366
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.
Perkins EJ; Posada M; Kellie Turner P; Chappell J; Ng WT; Twelves C
Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):355-367. PubMed ID: 29119333
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
[TBL] [Abstract][Full Text] [Related]
8. Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.
Gardin A; Ufer M; Legangneux E; Rossato G; Jin Y; Su Z; Pal P; Li W; Shakeri-Nejad K
Clin Pharmacokinet; 2019 Mar; 58(3):349-361. PubMed ID: 30088221
[TBL] [Abstract][Full Text] [Related]
9. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin.
Choi DH; Li C; Choi JS
J Pharm Pharmacol; 2010 Jul; 62(7):908-14. PubMed ID: 20636879
[TBL] [Abstract][Full Text] [Related]
10. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.
Castellan AC; Tod M; Gueyffier F; Audars M; Cambriels F; Kassaï B; Nony P;
Clin Pharmacokinet; 2013 Mar; 52(3):199-209. PubMed ID: 23344982
[TBL] [Abstract][Full Text] [Related]
11. S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults.
Tran L; Nikanjam M; Capparelli EV; Bertino JS; Nafziger AN; Kashuba ADM; Turpault S; Ma JD
Eur J Clin Pharmacol; 2021 Sep; 77(9):1349-1356. PubMed ID: 33754183
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations.
Huth F; Gardin A; Umehara K; He H
Clin Pharmacol Ther; 2019 Nov; 106(5):1113-1124. PubMed ID: 31199498
[TBL] [Abstract][Full Text] [Related]
13. [EVALUATION OF THE PHARMACOKINETIC INTERACTION OF AFOBAZOLE WITH CYP2C9 ENZYME DRUG SUBSTRATE OF CYTOCHROME P450].
Gribakina OG; Kolyvanov GB; Litvin AA; Smirnov VV; Shevchenko RV; Zherdev VP
Eksp Klin Farmakol; 2015; 78(12):18-22. PubMed ID: 27051923
[TBL] [Abstract][Full Text] [Related]
14. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Pharmacotherapy; 2003 Jun; 23(6):720-5. PubMed ID: 12820813
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism.
Cho CK; Kang P; Park HJ; Ko E; Mu CY; Lee YJ; Choi CI; Kim HS; Jang CG; Bae JW; Lee SY
Arch Pharm Res; 2022 May; 45(5):352-366. PubMed ID: 35639246
[TBL] [Abstract][Full Text] [Related]
16. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.
Han Y; Guo D; Chen Y; Chen Y; Tan ZR; Zhou HH
Eur J Clin Pharmacol; 2009 Jun; 65(6):585-91. PubMed ID: 19221727
[TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.
Kim YH; Kang P; Cho CK; Jung EH; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
Arch Pharm Res; 2021 Jul; 44(7):713-724. PubMed ID: 34304363
[TBL] [Abstract][Full Text] [Related]
18. Combination of losartan and puerarin induced pharmacokinetic interaction in hypertension rats enhances the antihypertensive effect of losartan.
Huang Y; Xue M
Xenobiotica; 2023 Mar; 53(3):201-206. PubMed ID: 37114483
[TBL] [Abstract][Full Text] [Related]
19. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
[TBL] [Abstract][Full Text] [Related]
20. Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.
Srinivas NR
Drug Dev Ind Pharm; 2016; 42(6):945-57. PubMed ID: 26467209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
